Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Recursion Pharmaceuticals, Inc. or Immunocore Holdings plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc compare based on key financial metrics to determine which better meets your investment needs.

About Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Latest Biotechnology and Recursion Pharmaceuticals, Inc., Immunocore Holdings plc Stock News

As of March 24, 2026, Recursion Pharmaceuticals, Inc. had a $1.7 billion market capitalization, compared to the Biotechnology median of $246.3 million. Recursion Pharmaceuticals, Inc.’s stock is down 22.5% in 2026, down 7.3% in the previous five trading days and down 52.55% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $74.7 million with a -863.4% net profit margin. Year-over-year quarterly sales growth most recently was 688.9%. Analysts expect adjusted earnings to reach $-0.986 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

As of March 24, 2026, Immunocore Holdings plc had a $1.5 billion market cap, putting it in the 52nd percentile of all stocks. Immunocore Holdings plc’s stock is down 13.7% in 2026, down 2.6% in the previous five trading days and up 0.45% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $400.0 million with a -8.9% net profit margin. Year-over-year quarterly sales growth most recently was 24.3%. Analysts expect adjusted earnings to reach $-0.928 per share for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

How We Compare Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc Stock Value Grades

Company	Ticker	Value
Recursion Pharmaceuticals, Inc.	RXRX	F
Immunocore Holdings plc	IMCR	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Recursion Pharmaceuticals, Inc. has a Value Score of 11, which is Ultra Expensive. Immunocore Holdings plc has a Value Score of 21, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc. or Immunocore Holdings plc has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc. or Immunocore Holdings plc is the better investment when it comes to value.

Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc’s Quality Grades

Company	Ticker	Quality
Recursion Pharmaceuticals, Inc.	RXRX	D
Immunocore Holdings plc	IMCR	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Recursion Pharmaceuticals, Inc. has a Quality Score of 25, which is Weak. Immunocore Holdings plc has a Quality Score of 42, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc. or Immunocore Holdings plc has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc. or Immunocore Holdings plc is the better investment when it comes to quality.

Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Recursion Pharmaceuticals, Inc.	RXRX	B
Immunocore Holdings plc	IMCR	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Recursion Pharmaceuticals, Inc. has a Earnings Estimate Score of 69, which is Positive. Immunocore Holdings plc has a Earnings Estimate Score of 30, which is Negative.

The Earnings Estimate Revisions Grade Winner: Recursion Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Recursion Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Immunocore Holdings plc. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Recursion Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc Grades

In addition to Estimate Revisions, Quality and Value, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Recursion Pharmaceuticals, Inc. or Immunocore Holdings plc Stock?

Overall, Recursion Pharmaceuticals, Inc. stock has a Value Score of 11, Estimate Revisions Score of 69 and Quality Score of 25.

Immunocore Holdings plc stock has a Value Score of 21, Estimate Revisions Score of 30 and Quality Score of 42.

Comparing Recursion Pharmaceuticals, Inc. and Immunocore Holdings plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.